EPZICOM - 53808-0767-1 - (abacavir sulfate and lamivudine)

Alphabetical Index


Drug Information of EPZICOM

Product NDC: 53808-0767
Proprietary Name: EPZICOM
Non Proprietary Name: abacavir sulfate and lamivudine
Active Ingredient(s): 600; 300    mg/1; mg/1 & nbsp;   abacavir sulfate and lamivudine
Administration Route(s): ORAL
Dosage Form(s): TABLET, FILM COATED
Coding System: National Drug Codes(NDC)

Labeler Information of EPZICOM

Product NDC: 53808-0767
Labeler Name: State of Florida DOH Central Pharmacy
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA021652
Marketing Category: NDA
Start Marketing Date: 20090701

Package Information of EPZICOM

Package NDC: 53808-0767-1
Package Description: 30 TABLET, FILM COATED in 1 BLISTER PACK (53808-0767-1)

NDC Information of EPZICOM

NDC Code 53808-0767-1
Proprietary Name EPZICOM
Package Description 30 TABLET, FILM COATED in 1 BLISTER PACK (53808-0767-1)
Product NDC 53808-0767
Product Type Name HUMAN PRESCRIPTION DRUG
Non Proprietary Name abacavir sulfate and lamivudine
Dosage Form Name TABLET, FILM COATED
Route Name ORAL
Start Marketing Date 20090701
Marketing Category Name NDA
Labeler Name State of Florida DOH Central Pharmacy
Substance Name ABACAVIR SULFATE; LAMIVUDINE
Strength Number 600; 300
Strength Unit mg/1; mg/1
Pharmaceutical Classes Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]

Complete Information of EPZICOM


General Information